Anna Protopapas

Anna Protopapas is an experienced leader in the biotechnology and pharmaceutical sectors, currently serving as a Board Member at Flare Therapeutics and Timberlyne Therapeutics since February and January 2025, respectively. Protopapas has held the position of Chairperson of the Board at Nuvalent, Inc. since March 2022 and has been a Board Member at Mersana Therapeutics since March 2015. Previous roles include Board Member at Dicerna Pharmaceuticals, Inc. during its acquisition by Novo Nordisk, Board Member at Bioverativ prior to its sale to Sanofi, and Board Member at ARIAD Pharmaceuticals before it was acquired by Takeda. Protopapas has also held significant executive roles, including President at Millennium: The Takeda Oncology Company and Executive Vice President at Takeda Pharmaceuticals America, Inc. Protopapas holds a Master of Science in Engineering from the Massachusetts Institute of Technology, a Bachelor of Science in Engineering from Princeton University, and an MBA from Stanford University Graduate School of Business.